Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Type I IFN stimulates IFI16-mediated aromatase expression in adipocytes that promotes E 2 -dependent growth of ER-positive breast cancer

Ka NL., Lim GY., Kim SS., Hwang S., Han J., Lee YH.

Prospective Study on Face & Skin, published in Cell Mol Life Sci (2022) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Cell Mol Life Sci (2022)
Reported sample size
—
Source database
Europe PMC
PMID
35593921
PMCID
PMC9122892
DOI
10.1007/s00018-022-04333-y
Citations
14

Abstract (original English)

Although type I interferons (IFNs) play multifaceted roles during tumorigenesis and cancer treatment, the interplay between type I IFNs and estrogen signaling in breast cancer (BC) microenvironment is not well understood. Here, we report a novel function of type I IFNs in inducing aromatase expression in adipose tissues surrounding BC, which potentiates the E 2 -dependent growth of estrogen receptor (ER)-positive BC. First, we found that expression levels of type I IFNs correlate negatively with clinical outcome but positively with tumor grade in patients with ER-positive BC. Levels of type I IFNs were elevated in cocultured media of immune cells and BC cells, which increased aromatase expression and E 2 production in Simpson-Golabi-Behmel syndrome preadipocytes. The type I IFN-induced aromatase expression was dependent on IFN-γ-inducible protein 16 (IFI16), which is encoded by an interferon-stimulated gene. At the molecular level, type I IFNs led to recruitment of HIF1α-IFI16-PRMT2 complex to the hypoxia-response element located in the aromatase PI.3/PII promoter. Next, we generated an adipocyte-specific Ifi204, which is a mouse ortholog of human IFI16, knockout mouse (Ifi204-AKO). IFNβ induced E 2 production in the preadipocytes isolated from the control mice, but such E 2 production was far lower in the Ifi204-AKO preadipocytes. Importantly, the growth of orthotopically inoc

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
BreastAdipocytesAnimalsHumansMiceBreast NeoplasmsAromataseInterferon Type INuclear ProteinsPhosphoproteins

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research